Skip to main content

Advertisement

Log in

Prevalence of cardiovascular risk factors in patients with psoriatic arthritis

  • Original Article
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

Psoriatic arthritis (PsA) is a chronic T cell-mediated inflammatory spondyloarthropathy affecting 10–40 % of psoriasis (PSO) patients (0.3–1.0 % of the general population). Recent epidemiological studies have shown an increased prevalence of cardiovascular (CV) risk factors and/or morbidity among PSO or PsA patients as compared to control individuals. The aim of this study is to describe the CV profile of PsA patients in Newfoundland, Canada. The possible impact of duration of chronic inflammation on CV variables was also explored. PsA patients were selected from a registry of PSO and PsA patients in Newfoundland. PsA patients diagnosed as per the CASPAR criteria are entered in the registry at the time of diagnosis, questioned on their medical history, and are followed indefinitely. Based on the duration since PsA diagnosis patients were classified as having early (<2 years) or established (≥2 years) PsA. CV risk was assessed using both conventional (hypertension, hypercholesterolemia, diabetes, obesity) and non-conventional (markers of chronic inflammation) factors. A total of 196 PsA patients were included; 42.9 % had early PsA and 57.1 % had established PsA. The prevalence of hypercholesterolemia, obesity, hypertension, diabetes mellitus, anxiety/depression, and coronary heart disease was 61.6, 59.7, 32.7, 13.8, 13.8, and 8.7 %, respectively. The prevalence of comorbidities was generally comparable between cohorts with exception of anxiety/depression, which was considerably higher in patients with established PsA compared to early PsA and obesity which was more common among male patients with established PsA. However, upon adjusting for age and gender differences, no statistically significant between-group differences were observed. Overall, these results suggest that PsA, even at early stages, is associated with significant CV comorbidity. These conditions should be taken into consideration when assessing the PsA burden of illness in epidemiological and health outcomes studies. Furthermore, early detection and management of these conditions could improve the patients’ disability and quality of life.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. National Psoriasis Foundation. Statistics. In. 2014.

  2. Khraishi M, Chouela E, Bejar M, Landells I, Hewhook T, Rampakakis E, Sampalis JS, Abouchehade K (2012) High prevalence of psoriatic arthritis in a cohort of patients with psoriasis seen in a dermatology practice. J Cutan Med Surg 16:122–127

    PubMed  Google Scholar 

  3. Mease PJ, Gladman DD, Papp KA, Khraishi MM, Thaci D, Behrens F, Northington R, Fuiman J, Bananis E, Boggs R, Alvarez D (2013) Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics. J Am Acad Dermatol 69:729–735

    Article  PubMed  Google Scholar 

  4. Prodanovich S, Kirsner RS, Kravetz JD, Ma F, Martinez L, Federman DG (2009) Association of psoriasis with coronary artery, cerebrovascular, and peripheral vascular diseases and mortality. Arch Dermatol 145:700–703

    Article  PubMed  Google Scholar 

  5. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB (2006) Risk of myocardial infarction in patients with psoriasis. JAMA 296:1735–1741

    Article  PubMed  CAS  Google Scholar 

  6. Christophers E (2007) Comorbidities in psoriasis. Clin Dermatol 25:529–534

    Article  PubMed  Google Scholar 

  7. Kim N, Thrash B, Menter A (2010) Comorbidities in psoriasis patients. Semin Cutan Med Surg 29:10–15

    Article  PubMed  CAS  Google Scholar 

  8. Vena GA, Vestita M, Cassano N (2010) Psoriasis and cardiovascular disease. Dermatol Ther 23:144–151

    Article  PubMed  Google Scholar 

  9. Wong K, Gladman DD, Husted J, Long JA, Farewell VT (1997) Mortality studies in psoriatic arthritis: results from a single outpatient clinic. I. Causes and risk of death. Arthritis Rheum 40:1868–1872

    Article  PubMed  CAS  Google Scholar 

  10. Han C, Robinson DW Jr, Hackett MV, Paramore LC, Fraeman KH, Bala MV (2006) Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol 33:2167–2172

    PubMed  Google Scholar 

  11. Khraishi M, MacDonald D, Rampakakis E, Vaillancourt J, Sampalis JS (2011) Prevalence of patient-reported comorbidities in early and established psoriatic arthritis cohorts. Clin Rheumatol 30:877–885

    Article  PubMed  Google Scholar 

  12. Kondratiouk S, Udaltsova N, Klatsky AL (2008) Associations of psoriatic arthritis and cardiovascular conditions in a large population. Perm J 12:4–8

    PubMed  PubMed Central  Google Scholar 

  13. Gladman DD, Ang M, Su L, Tom BD, Schentag CT, Farewell VT (2009) Cardiovascular morbidity in psoriatic arthritis. Ann Rheum Dis 68:1131–1135

    Article  PubMed  CAS  Google Scholar 

  14. Husted JA, Thavaneswaran A, Chandran V, Eder L, Rosen CF, Cook RJ, Gladman DD (2011) Cardiovascular and other comorbidities in patients with psoriatic arthritis: a comparison with patients with psoriasis. Arthritis Care Res (Hoboken ) 63:1729–1735

    Article  Google Scholar 

  15. Gonzalez-Juanatey C, Llorca J, Migo-Diaz E, Dierssen T, Martin J, Gonzalez-Gay MA (2007) High prevalence of subclinical atherosclerosis in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. Arthritis Rheum 57:1074–1080

    Article  PubMed  Google Scholar 

  16. Tam LS, Shang Q, Li EK, Tomlinson B, Chu TT, Li M, Leung YY, Kwok LW, Wong KC, Li TK, Yu T, Zhu TY, Kun EW, Yip GW, Yu CM (2008) Subclinical carotid atherosclerosis in patients with psoriatic arthritis. Arthritis Rheum 59:1322–1331

    Article  PubMed  Google Scholar 

  17. Peters MJ, Van der Horst-Bruinsma IE, Dijkmans BA, Nurmohamed MT (2004) Cardiovascular risk profile of patients with spondylarthropathies, particularly ankylosing spondylitis and psoriatic arthritis. Semin Arthritis Rheum 34:585–592

    Article  PubMed  Google Scholar 

  18. Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H (2006) Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 54:2665–2673

    Article  PubMed  Google Scholar 

Download references

Conflict of interest

Majed Khraishi is partially funded by non-restricted grants from Abbott Canada, Amgen/Wyeth Canada, and Wyeth (later Pfizer) and supported by JSS Medical Research Inc. Rana Aslanov declared none. Emmanouil Rampakakis, Clare Pollock, and John S. Sampalis are employees of JSS Medical Research Inc.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Majed Khraishi.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Khraishi, M., Aslanov, R., Rampakakis, E. et al. Prevalence of cardiovascular risk factors in patients with psoriatic arthritis. Clin Rheumatol 33, 1495–1500 (2014). https://doi.org/10.1007/s10067-014-2743-7

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-014-2743-7

Keywords

Navigation